Aligos Therapeutics Receives FDA Fast Track Designation for HBV Drug, Phase 2 Study Continues with Increased Sample Size

summarizeSummary

Aligos Therapeutics announced that its lead HBV drug candidate, pevifoscorvir sodium, received FDA Fast Track Designation, and its Phase 2 B-SUPREME study will continue with an increased sample size after not meeting futility criteria.

check_boxKey Events

• FDA Grants Fast Track Designation

  The U.S. Food and Drug Administration (FDA) granted Fast Track Designation to pevifoscorvir sodium, Aligos' lead drug candidate for chronic hepatitis B virus (HBV) infection. This designation aims to expedite development and review for drugs addressing serious conditions with unmet medical needs.

• Phase 2 Study Recommended for Continuation

  The independent Data Safety Monitoring Review Board (DSMB) recommended the continuation of the Phase 2 B-SUPREME study for pevifoscorvir sodium. The study's futility criteria were not met, and the DSMB advised increasing the sample size for the HBeAg- cohort from 74 to 100 participants to optimize statistical powering.

• Positive Safety Profile Observed

  Interim analysis showed that the study drugs were well-tolerated by participants, with no clinically concerning laboratory, physical examination, vital sign, or ECG abnormalities, and no viral breakthrough related to the study drugs observed to date.

• Topline Data Expected in 2027

  Despite the sample size increase, the company reiterated that topline data from the Phase 2 B-SUPREME study remains on track for 2027.

auto_awesomeAnalysis

This 8-K provides critical positive updates for Aligos Therapeutics, especially in light of the 'going concern' warning and limited cash runway disclosed in its recent 10-K. The FDA's Fast Track Designation for pevifoscorvir sodium significantly de-risks the development pathway, potentially accelerating regulatory review and approval for their lead chronic HBV candidate. Furthermore, the independent Data Safety Monitoring Review Board's recommendation to continue the Phase 2 B-SUPREME study, coupled with not meeting futility criteria and an increased sample size, indicates continued confidence in the drug's potential efficacy and safety. These developments are crucial for the company's ability to attract future funding and extend its operational runway.